| Bari-kuma Queen Kpea, NP | |
|
1968 Peachtree Rd Nw, Atlanta, GA 30309-1281 | |
| (404) 605-5000 | |
| Not Available |
| Full Name | Bari-kuma Queen Kpea |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 1968 Peachtree Rd Nw, Atlanta, Georgia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679341499 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | RN287456 (Georgia) | Secondary |
| 363L00000X | Nurse Practitioner | RN287456 (Georgia) | Primary |
| Entity Name | Piedmont Cardiology Of Atlanta, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275729691 PECOS PAC ID: 0345321691 Enrollment ID: O20080114000153 |
News Archive
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the European Commission has granted a marketing authorization for the oral receptor tyrosine kinase inhibitor LENVIMA (lenvatinib mesylate) as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.
Oncotarget Volume 11, Issue 11 reported that in this preclinical study, we characterized the binding affinity and selectivity of quizartinib, a small-molecule inhibitor of FLT3, and AC886, the active metabolite of quizartinib, compared with those of other FLT3 inhibitors.
Researchers of the University of Granada have developed a new computer program that allows early diagnosis of Alzheimer's disease through processed images.
Malawi's health care system is "facing major setbacks" after the U.K.'s Department for International Development (DFID) made its final aid disbursement to the country in March and decided not to renew a six-year spending commitment that ends this month, IRIN reports. DFID, which provided approximately $122 million to Malawi annually, was the country's largest donor.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bari-kuma Queen Kpea, NP 161 Ashland Creek Ct., Lawrenceville, GA 30045 Ph: (678) 779-5950 | Bari-kuma Queen Kpea, NP 1968 Peachtree Rd Nw, Atlanta, GA 30309-1281 Ph: (404) 605-5000 |
News Archive
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the European Commission has granted a marketing authorization for the oral receptor tyrosine kinase inhibitor LENVIMA (lenvatinib mesylate) as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.
Oncotarget Volume 11, Issue 11 reported that in this preclinical study, we characterized the binding affinity and selectivity of quizartinib, a small-molecule inhibitor of FLT3, and AC886, the active metabolite of quizartinib, compared with those of other FLT3 inhibitors.
Researchers of the University of Granada have developed a new computer program that allows early diagnosis of Alzheimer's disease through processed images.
Malawi's health care system is "facing major setbacks" after the U.K.'s Department for International Development (DFID) made its final aid disbursement to the country in March and decided not to renew a six-year spending commitment that ends this month, IRIN reports. DFID, which provided approximately $122 million to Malawi annually, was the country's largest donor.
› Verified 4 days ago